$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens from a defined library; PV-10 produces antigens present in an injected tumor that may extend beyond what's contained in the library
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA presumably is based on genomic profiling of a single tumor; PV-10 produces antigens specific to each injected tumor
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigens, but presumably does not produce co-stimulatory factors; PV-10 produces antigens + multiple co-stimulatory factors, such as DAMPs (damage-associated molecular patterns)
$PVCT ITU PV-10 v $MRNA cancer vaccine: mRNA produces antigenic material without the context of the TME (tumor microenvironment); PV-10 produces antigens from within the TME
1/ Continuing our thread about what we believe are the differences between $PVCT’s intratumoral (ITU) PV-10 cancer immunotherapy and $MRNA intramuscular (IM) mRNA-4157 cancer vaccine. #rosebengal#rosebengalsodium.
2/ The Venn diagrams below illustrate the immune activation potential as a proportion of the total available drivers of anti-tumor activation of [LEFT] $MRNA’s IM mRNA-4157 [yellow] and [RIGHT] $PVCT’s ITU PV-10 [magenta].
3/ $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #1: the extent of tumor epitopes sampled when creating mRNA-4157 from and for a patient vs the extent sampled when injecting multiple tumors of each and every patient with PV-10.
4/ $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #2: the single mode of activation (i.e., only antigen production) by mRNA-4157 vs an orchestrated, multimodal activation (i.e., release of tumor antigens & immune upregulating agents) by PV-10.
5/a $PVCT’s ITU PV-10 [magenta] vs $MRNA’s IM mRNA-4157 [yellow]: Key difference #3: $MRNA’s mRNA-4157 activation is divorced from the context of actual tumor tissue. mRNA-4157 is administered intramuscularly, which is not necessarily proximate to tumor tissue.
5/b Whereas, the signaling resulting from $PVCT’s ITU PV-10 is released from actual tumor because the actual tumor is injected with PV-10. #rosebengal#rosebengalsodium.
5/c Impacting actual tumor tissue (by $PVCT’s ITU PV-10’s injection) is likely to have secondary influence on the recruitment of immune components (such as dendritic cells) and effective training of an adaptive response (i.e., functional CD8+ T cells) against tumor.
6a/ The illustrations below endeavor to characterize what appears to be the one-size-fits-all nature of $MRNA’s IM mRNA-4157 [LEFT], which is precisely matched to a subset of potential immune markers from a specific tumor, compared to $PVCT’s ITU PV-10 [RIGHT].
6b/ $MRNA’s IM mRNA-4157’s precision may actually compromise activity against other tumor epitopes (i.e., genomic variants, which are represented by different size nuts in the LEFT illustration).
6c/ In contrast, by deploying $PVCT’s ITU PV-10 against a broad range of a patient's tumor burden (the RIGHT illustration), precise education of the immune system to produce T cells functional against each injected tumor epitope is possible.
2/ Abstract Number: 606 - B0243. Echeverri Tribin F et al. Inhibition of Multidrug-Resistant Pseudomonas aeruginosa with Rose Bengal Photodynamic Antimicrobial Therapy: In vitro. Conclusions: MDR Pseudomonas aeruginosa can be inhibited by rose bengal eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
3/ Abstract Number: 609 - B0246. Krishna et al. In vitro Inhibition of Aspergillus and Fusarium Species with Erythrosin B, Eosin Y, and Rose Bengal Photodynamic Antimicrobial Therapy. Conclusions: EB, EY, and RB with light were effective against both F. eppro02.ativ.me/web/page.php?p…… twitter.com/i/web/status/1…
2/ “Everyone” seems to know or understand #RoseBengal, but do they (you) really?
3/ #RoseBengal is a small molecule (i.e., <1,000 Daltons*), but a “heavy” one at 973.67 Da or g/mol. It is heavy because of its four iodides, which comprise 52% of its molecular weight.
1/ “Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy.” $PVCT thoughts: there’s no free lunch. A THREAD.
2/ 20Mar23: Endpoints: “BioNTech to pay $200M upfront in CTLA-4 antibody development, commercialization deal.” endpts.com/biontech-to-pa….
$PVCT-related medical journal article: DePalo DK, Zager JS. Advances in Intralesional Therapy for Locoregionally Advanced and Metastatic Melanoma: Five Years of Progress. Cancers. 2023; 15(5):1404. doi.org/10.3390/cancer…. @MoffittNews@USFHealthMed. Intralesional agent PV-10… twitter.com/i/web/status/1…
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-naïve Stage III cutaneous melanoma
Other $PVCT work by Dr. Zager (and Moffitt Cancer Center) as a principal investigator for us: PV-10 (#RoseBengalSodium) + #Keytruda (#pembrolizumab) for immune checkpoint blockade-refractory advanced melanoma
2/ Over the past decade-plus, cancer immunotherapy with antibodies targeting the PD-1 immune checkpoint pathway (i.e., PD-1 inhibitors #PD1) has yielded dramatic improvement in clinical outcome for many patients with #CutaneousMelanoma. #Keytruda#Opdivo#otherPD1s#PDL1s
3/ However, patients with Stage III disease and, in particular, those with in-transit disease (i.e., in-transit melanoma; ITM #IntransitMelanoma), have presented unique challenges with regard to response rate and durability of response.
2/ This $PVCT #thread will be an ongoing one for some time. Please check back to read it again (and again), and learn more about our medical scientific history and our lead molecule #RoseBengalSodium’s journey to becoming a multi-disease, broad-spectrum, therapeutic compound.
3/ #Covid has been a deeply painful experience, to say the least, for the U.S. and the world. It also marked a turning point in the advancement and expansion of our #HX medical science platform, as well as our lead molecule #RoseBengalSodium and the investigational drugs and drug… twitter.com/i/web/status/1…